Apollomics Inc Dossier
Qualitative Analysis
Business overview
Apollomics Inc. (Nasdaq: APLM) is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies designed to transform the treatment landscape for patients with difficult-to-treat and treatment-resistant cancers. The company's pipeline is built around targeted therapies and immuno-oncology approaches that harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics' core product candidate is vebreltinib (APL-101), a highly potent, selective, and central nervous system (CNS)-penetrant c-MET inhibitor currently being evaluated in the global Phase 2 SPARTA trial for non-small cell lung cancer (NSCLC) and other solid tumors with MET dysregulation. Additionally, the company is developing uproleselan (APL-106), a specific E-Selectin antagonist designed to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia (AML).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the global clinical development of vebreltinib (APL-101), a highly potent and selective c-MET inhibitor, through the ongoing Phase 2 SPARTA trial across approximately 25 study sites in over 10 countries.
Expected impact: Aims to maximize the therapeutic potential of vebreltinib across multiple tumor types (including NSCLC and brain tumors with MET alterations) to support future regulatory submissions in the U.S., EU, and other major markets.
Implementing significant cost reduction initiatives to streamline operations, enhance financial discipline, and extend the company's cash runway.
Expected impact: Successfully reduced full-year 2025 operating expenses by 64% year-over-year (to $19.8 million from $55.7 million in 2024) and narrowed the net loss to $10.9 million.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
LaunXP received exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong, and Macau) for the treatment of NSCLC.
Terms: Apollomics received a $10.0 million upfront payment and is eligible for up to $50.0 million in regulatory and pre-commercial milestones, plus royalties on net product sales.
Apollomics terminated its development and license agreement with Edison regarding APL-122 in December 2025 due to alleged non-performance by Edison.
Terms: The termination is not expected to have a material adverse effect on Apollomics' overall financial condition or results of operations.